BlackRock’s Aevi Genomic Medicine Inc GNMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-683,551
| Closed | -$100K | – | 5163 |
|
|
2019
Q4 | $100K | Buy |
683,551
+387
| +0.1% | +$53 | ﹤0.01% | 4450 |
|
|
2019
Q3 | $102K | Buy |
683,164
+1,239
| +0.2% | +$224 | ﹤0.01% | 4443 |
|
|
2019
Q2 | $109K | Sell |
681,925
-96,925
| -12% | -$19.6K | ﹤0.01% | 4459 |
|
|
2019
Q1 | $153K | Sell |
778,850
-5,297
| -0.7% | -$1.18K | ﹤0.01% | 4293 |
|
|
2018
Q4 | $548K | Buy |
784,147
+1,002
| +0.1% | +$1.12K | ﹤0.01% | 4054 |
|
|
2018
Q3 | $963K | Buy |
783,145
+4,773
| +0.6% | +$5.34K | ﹤0.01% | 3972 |
|
|
2018
Q2 | $863K | Buy |
778,372
+39,493
| +5% | +$60K | ﹤0.01% | 3955 |
|
|
2018
Q1 | $1.49M | Sell |
738,879
-2,837
| -0.4% | -$5.33K | ﹤0.01% | 3774 |
|
|
2017
Q4 | $890K | Buy |
741,716
+3,092
| +0.4% | +$4.22K | ﹤0.01% | 3932 |
|
|
2017
Q3 | $931K | Sell |
738,624
-2,081
| -0.3% | -$2.66K | ﹤0.01% | 3933 |
|
|
2017
Q2 | $986K | Sell |
740,705
-1,278,158
| -63% | -$1.85M | ﹤0.01% | 3853 |
|
|
2017
Q1 | $3.75M | Buy |
2,018,863
+2,017,163
| +118,657% | +$9.13M | ﹤0.01% | 3473 |
|
|
2016
Q4 | $9K | Sell |
1,700
-430
| -20% | -$2.26K | ﹤0.01% | 3427 |
|
|
2016
Q3 | $12K | Buy |
2,130
+602
| +39% | +$3.43K | ﹤0.01% | 3377 |
|
|
2016
Q2 | $8K | Buy |
1,528
+1,218
| +393% | +$6.4K | ﹤0.01% | 3455 |
|
|
2016
Q1 | $1K | Buy |
+310
| New | +$1.28K | ﹤0.01% | 3602 |
|
BlackRock's GNMX Position: Q1 2020 in Review
BlackRock sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2020, closing a stake of 683,551 shares — an estimated $100K sold.
BlackRock first reported a position in GNMX in Q1 2016 and held it in 16 quarters. The position peaked at $3.75M in Q1 2017. 2 funds tracked by Wall St. Rank hold GNMX as of Q1 2020.
- BlackRock reported no remaining Aevi Genomic Medicine Inc position as of Q1 2020 after selling out during the quarter.
- BlackRock sold 683,551 Aevi Genomic Medicine Inc shares in Q1 2020, an estimated $100K.
- BlackRock first reported a position in Aevi Genomic Medicine Inc in Q1 2016 and held it in 16 quarters.
- BlackRock's Aevi Genomic Medicine Inc position peaked at $3.75M in Q1 2017.
- 2 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2020.
Based on BlackRock's 13F filing for Q1 2020, filed 1 May 2020.